

Review

Open Access

Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression

Rudolf Götz

Address: Institut für Medizinische Strahlenkunde und Zellforschung (MSZ), Universität Würzburg, Versbacher Straße 5, 97078 Würzburg, Germany

Email: Rudolf Götz - goetz@mail.uni-wuerzburg.de

Published: 20 May 2008

Received: 28 January 2008

Cancer Cell International 2008, **8**:7 doi:10.1186/1475-2867-8-7

Accepted: 20 May 2008

This article is available from: <http://www.cancerci.com/content/8/1/7>

© 2008 Götz; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Cadherin cell adhesion molecules play an essential role in creating tight intercellular association and their loss has been correlated with poor prognosis in human cancer. Mutational activation of protein kinases and loss of cell adhesion occur together in human lung adenocarcinoma but how these two pathways interconnect is only poorly understood. Mouse models of human lung adenocarcinoma with oncogene expression targeted to subtypes of lung epithelial cells led to formation of adenomas or adenocarcinomas that lacked metastatic potential. Conditional genetic abrogation of epithelial tumour cell adhesion in mice with benign lung tumours induced by oncogenic RAF kinase has been demonstrated to induce intratumourous vascularization (angiogenic switch), progression to invasive adenocarcinoma and micrometastasis. Importantly, breaking cell adhesion in benign oncogene-driven lung tumour cells activated β -catenin signalling and induced the expression of several genes that are normally expressed in intestine rather than the lung. I will discuss potential routes to nuclear β -catenin signalling in cancer and how nuclear β -catenin may epigenetically alter the plasticity of tumour cells during malignant progression.

Background

Lung cancer has become the most prevalent neoplasm throughout the world with 1,2 million deaths per year [1]. Non-small-cell lung cancer (NSCLC), with its main subtypes adenocarcinoma, squamous cell and large-cell carcinoma is the most frequent type ($\sim 80\%$) of lung cancer with high metastatic potential and low cure rate. As is true for most types of cancer, clinical onset of disease is noted typically in people at an age over-fifties [2]. Since the incidence of lung cancer was very low only five generations ago, it is clear that changes in life style have caused the surge of this disease [3]. Cigarette smoking is a major cause of lung cancer, but about 25% of lung cancer cases are found in non-smokers [4] and these may be attributable to passive smoking or other environmental causes. Quite often, the primary lung tumour is inoperable at the

time of diagnosis because regional lymphatic and distant organ metastases are already present [5]. Thus, progressed disease state may in part explain the high mortality rates. The knowledge of the cellular and genetic origin of lung cancer is incomplete, because its detection in early stages using computer tomography scans is only in its beginnings [6]. Significant progress has been made in identifying genetic lesions in lung cancer by sequencing-based mutation screening [7] and by characterizing copy-number alterations [8]. Mouse models of the human disease offer the opportunity that the effects of oncogenes or other genetic and epigenetic factors thought to underlie the hallmarks of lung cancer can be studied and stages of disease progression can presumably be identified [9]. Furthermore, mouse modelling of human lung cancer provides a potentially powerful system for evaluation of

novel therapeutic agents that may be clinically useful. Finally, such mice will be valuable tools to identify the origin of the cell(s) from which a lung tumour arises, the cancer stem cell or tumour initiating cell [10,11].

Target cells for oncogenic transformation in the distal mouse lung

The major function of the lung is gas exchange. The epithelial cells which line the tree of tubules and alveolar units arise from progenitor cells present in the lung bud of the ventral foregut endoderm. During embryonic development, they form the epithelial lining of the conducting airways and the distal vascularized sac-like structures. At birth, fluid is resorbed from these sacs to expose a functional gas exchange surface. The subsequent postnatal maturation of the lung involves the formation of septa in the terminal sacs (alveogenesis) leading to an expansion of the gas exchange surface [12]. Thus, in the adult lung distinct types of epithelial cells line the trachea, bronchi, bronchioli and alveoli. The alveolar regions of the human lung make up a surface of roughly 100 m², whereas the conducting airways cover less than 1% of this surface. Early studies [13] on the nuclear incorporation of radio labelled nucleotides and the maintenance of the label-retaining cells in pulse-chase experiments showed that epithelial cells of the mature rodent lung have a half-life of about 100 days and that there could exist distinct types of label-retaining cells – that may be stem cells – in different anatomical regions of the adult lung. In line with this notion, in case of injury or cell death caused by infections, quiescent cells start to proliferate and replace the lost cells. The topic of lung epithelial stem cells has been reviewed recently elsewhere [14,15]. Alveolar type II pneumocytes secrete a variety of pulmonary surfactant proteins (SP), for example SP-C [16]. Type II cells are also the precursors of type I cells which form the thin diffusion barrier important for gas exchange in the alveolus (Figure 1). In mice, SP-C expression is not restricted to type II cells, since rare cells located at the bronchio-alveolar duct junction (BADJ, Figure 1) co-express SP-C together with the Clara cell antigen CC10, a marker specific for Clara cells, another epithelial cell that normally lines the bronchi and bronchioles [17]. The double-positive cell pool has been shown to be resistant to naphthalene treatment which destroys all other Clara cells lining the bronchus and the terminal bronchioles. Furthermore, these cells have been isolated based on their Sca1/CD34 phenotype and been shown to be capable of self-renewal and differentiation in vitro and thus have been called bronchio-alveolar stem cells (BASCs, [18]). BASCs may however be only one of several cell types that have stem cell properties and can repair injured lung. Type II cells have also been shown to re-enter the cell cycle and proliferate in radiation-induced alveolar injury [19] and in bleomycin-induced destruction of type I and type II alveolar cells [18,20]. During




Figure 1
Epithelial cell types in the distal mouse lung. Epithelial cell types present in the distal lung that might be target cells for oncogenic transformation are the bronchio-alveolar stem cell (BASC) that localizes to the bronchio-alveolar duct junction (BADJ) and more differentiated cells with specific functions such as type II pneumocytes and Clara cells. The cuboidal alveolar type II cells as well as the columnar Clara cell may assume progenitor cell status in case of injury. Whether terminally differentiated type I pneumocytes can be recruited into tumours is not known.

repair of alveolar damage, type II cells differentiate into type I cells. It is notable, that type II alveolar cells proliferate in idiopathic pulmonary fibrosis, a proliferative lung disease [21].

Mutations in NSCLC and their corresponding mouse models

I will focus here on genes specifying components of the classical mitogen activated protein kinase (MAPK) signaling cascade which are among those most frequently over-expressed, amplified or mutated in NSCLC (Figure 2). Starting at the cell surface, overexpression of members of the ErbB receptor family, most notably the epidermal growth factor receptor (EGFR), and of some of its ligands, such as EGF and TGF- α , has been observed [8,22]. In addition, mutations have been detected in NSCLC samples in the kinase domain of the EGFR gene [23-25]. These mutations endow the receptor with increased kinase activity




Figure 2
Mutation frequency in NSCLC. Frequency of activating point mutations and copy number amplifications found in NSCLC in genes specifying components of the classical mitogen activated protein kinase (MAPK) signaling cascade. The majority of alterations are point mutations that convert the proto-oncogene into a constitutive active oncogenic form. Frequencies for mutation-activated β -catenin (CTNNB1) and silencing of the promoter region of *CDH1* encoding E-Cadherin are shown. Data are derived from literature and the COSMIC database (version 35).

and lead to hyperactivation of downstream signalling cascades. The EGFR active site mutants transform fibroblasts and tracheobronchiolar epithelial cells [26]. Similar findings have been reported for ERBB2 mutations [27] that occur in approximately 2% of NSCLC [28]. Inducible expression of the EGFR active site mutants in transgenic mice has been achieved. Using the tetracycline-inducible system where the transcriptional activator rTA was expressed under the CC10 promoter [29], conditional expression of EGFR active site mutant proteins in adult lungs led to adenocarcinoma formation [30,31].

RAS is a small GTP-binding protein tethered to the inner cell membrane that couples growth factor receptor activation to the downstream RAF-MEK-ERK MAPK cascade (Figure 3). Besides the RAF kinases, several other classes of proteins have been implicated as effectors of RAS [32]. When activated by specific growth factors (for example EGF), the fraction of RAS in the activated RAS-GTP form increases at the expense of the inactive RAS-GDP form. A high proportion of human cancers including those of the lung carry activating point mutations in RAS (Figure 2) [33]. These mutations result in the loss of the intrinsic GTPase activity that is needed to return RAS to its inactive GDP-bound state, leaving the mutated RAS permanently active [34]. Several strains of mice with inducible alleles of oncogenic *K-RasG12D* or *K-RasG12V* have been generated [9]. A transcriptional stop element flanked by loxP sites present in the targeted "floxed" allele prevented the expression of the oncogene. The removal of the stop element was achieved either "systemically" (in compound mice harbouring also a Cre recombinase transgene) or through infection of the lungs with recombinant adenovirus expressing Cre recombinase. One of the mouse models allowed for the histochemical visualisation of the cells that expressed the oncogenic *K-RasG12V* allele. Despite widespread lung-targeted expression of RAS oncoprotein upon activation of the oncogenic *K-RasG12V* allele, the majority of the cells expressing the RAS oncoprotein did not gain a proliferative advantage and only few adenomas formed in the lung [35]. Since a substantial number of cells in premalignant tumours underwent oncogene-induced senescence, it has been proposed that this mechanism might limit tumour initiation and/or tumour progression from premalignant adenomas to malignant adenocarcinomas [36]. None of the RAS mouse models showed any evidence for metastatic spread of the tumours. Notably, human lung cancer with *K-RAS* mutations do not appear to progress, either [37].

RAF is a serine-threonine kinase that is activated downstream of RAS [38,39]. RAF activates the kinase MEK (MAP kinase extracellular signal-regulated kinase) which then activates ERK (extracellular signal-regulated kinase, Figure 3). In mammals there exist three structurally simi-




Figure 3
Regulation of cell adhesion by RAS/MAPK, RAS/PI3K/AKT and β -catenin signalling. In lung NSCLC, constitutive signalling is caused by mutational activation of components of the RAS/MAPK and/or RAS/PI3K/AKT pathways that endows tumour cells with enhanced proliferation and survival in the absence of a growth factor (GF). Loss of E-cadherin expression and disruption of a functional E-cadherin complex at the adherens junction are two events that occur in human lung cancers. Inducible disruption of the functional E-cadherin complex in a RAF oncogene-driven NSCLC mouse model led to the loss of adherens junction function and deadhesion of neighbouring tumour cells. In addition, nuclear β -catenin activity was instrumental for increased proliferation and survival of tumour cells, as well as the induction of angiogenic factors that facilitated the growth of a tumour vasculature (angiogenic switch) and changes in cell fate integrity (dysplasia).

lar RAF kinases, A-RAF, B-RAF and C-RAF. Inactivation of the corresponding genes in mice indicates that the three genes fulfil distinct roles [40]. Of the RAF family of protein kinases, B-RAF is the only member to be frequently (~8%) activated by mutation in cancer [41]. Mutations in A-RAF have not been found [42] and mutations in C-RAF are rare in human cancers [43], but C-RAF is overexpressed in ovarian and pulmonary carcinomas [44,45]. The fact that B-RAF can be activated by a single amino acid change, whereas C-RAF and A-RAF require two mutations for oncogenic activation is thought to explain the difference in mutation frequency. Mice expressing in the lung the most common oncogenic B-RAF mutation, B-RAFV600E, have been established [46,47]. One model employed a conditional targeted allele of oncogenic B-RAFV600E containing a floxed transcriptional stop element. Lungs infected with an adenovirus expressing Cre recombinase developed benign tumours that grew rapidly for about eight weeks and then showed signs of oncogene-induced senescence (positive staining for p19^{ARF} and Mec1; [46]). The second model used compound mice with switchable (doxycycline-dependent) induction of B-RAFV600E expression controlled by the CC10 promoter. Administration of doxycycline for six weeks led to the formation of adenomas, which regressed upon withdrawal of doxycycline due to tumour cell apoptosis [47].

In another NSCLC model for oncogenic RAF, the SP-C promoter-directed the expression of an oncogenic variant of C-RAF, called C-RAF BXB [48]. The homeodomain containing thyroid transcription factor 1, also called Nkx2.1, controls the SP-C promoter and confers lung-specific gene expression [49]. Importantly, *NKX2.1* has been found to be amplified in a significant number of lung adenocarcinoma samples [8,50]. Conversely, lungs in *Nkx2.1* deficient mice have only two main bronchi and instead of an epithelial tree, cystic structures with columnar cells form and surfactant protein genes fail to be expressed [51]. The SP-C promoter is active in the developing lung bud at embryonic day E11 and in the subsequent stages of embryonic lung development and postnatal lung maturation, as well as in alveolar type II pneumocytes of adult lung [52,53]. In the SP-C C-RAF BXB transgenic mouse, lung development proceeds normally despite the fact that the SP-C promoter is active during embryonic development. Lung tumour initiation occurs in postnatal mice at an age of about one week, but only a small fraction of pneumocytes can be transformed. Several hundred adenomas are forming in each lung, consisting of cuboidal, SP-C expressing type II-like cells. Whether the rare adenoma initiation is due to the fact that only a small pool of type II-like cells is susceptible to transformation or results from mosaic C-RAF-BXB expression is currently unclear. Neither impaired alveolar morphology nor function has been noted in the vast majority of pneumocytes. The ade-

nomas grow continuously because a significant fraction of tumour cells is proliferating [54]. The tumour cells did not show overt signs of apoptosis [55,56]. Progression of the adenomas towards adenocarcinomas was only observed upon inactivation of p53 [57], similar to observations made in lung epithelium expressing oncogenic B-RAF [46]. No further progression towards malignancy, such as intravasation into the lymphatic or blood vasculature and outgrowth of organ metastasis has been observed [54], not even after a period of more than 12 months of continuous lung tumour growth [54]. Thus, the adenomas of the SP-C C-RAF BXB model contain proliferating and surviving epithelial tumour cells, making the model suitable to identify tumour progression factors in lung tumorigenesis. Importantly, the adenomas resemble atypical adenomatous hyperplasia in human lung. Such lesions have been detected incidentally in resected human lung [58] and more recently on a larger scale as a result of computer tomography screening [6]. In sum, mutations along the growth factor receptor kinase-RAS-RAF axis together account for more than 50% of all NSCLC cases. They appear to be functional equivalent as they are nonoverlapping underscoring the important role of this pathway in human lung cancer (Figure 3).

Increased growth factor receptor or RAS signalling not only activates RAF but in addition phosphoinositide-3-kinase (PI3K, Figure 3). PI3K family proteins catalyze the phosphorylation of the 3-position of the inositol ring in phosphoinositide substrates [59]. These phospholipid second messengers recruit the serine/threonine protein kinase B (PKB, also known as AKT) to the cell membrane where its activation by other kinases occurs [60]. Active AKT phosphorylates a variety of proteins that mediate increased cell proliferation and cell survival [60]. Aberrant activation of the PI3K/AKT pathway has been implicated in lung cancer progression [61-63]. Conversely, the PI3K antagonistic enzyme PTEN (phosphatase and tensin homolog) is lost by mutations, deletions or promoter methylation at high frequency in human lung cancer [63-65]. Mice with *K-RasG12D* oncogene activation with a PI3K unable to interact with RAS only formed premalignant lesions but no macroscopic lung tumours [66].

Breaking the cadherin adhesion complex in RAF-driven adenomas

In haematoxylin-eosin stained tissue sections of adenomas from SP-C C-RAF BXB mice, neighbouring tumour cells seemed to be in direct contact and therefore probably maintained the expression of adhesion molecules. Immunostaining revealed that E-cadherin was indeed expressed uniformly in the adenomas of SP-C C-RAF BXB mice [54]. E-cadherin is the dominant cadherin in epithelial tissues [67]. The extracellular part of E-cadherin forms calcium-dependent homophilic dimers thus mediating cell-to-cell

adhesion and joining neighbouring epithelial cells. The cytoplasmic domain of E-cadherin is organized in a heteromeric complex with β -catenin bound directly to a conserved sequence in the distal part of its cytoplasmic domain and α -catenin, a relative of vinculin, bound to the N-terminus of β -catenin. E-cadherin and β -catenin are phosphoproteins and phosphorylation acts as a biochemical switch to regulate complex formation at adherens junctions and shuttling between subcellular destinations (see below). Indeed, mutational analysis of a serine-rich catenin-binding domain of cadherin revealed that serine phosphorylation is important for E-cadherin-catenin interaction [68]. It appears that soon after translation, β -

catenin – α -catenin dimers form a complex with cadherin before being transported to the cell surface [69]. This core complex at the adherens junction (Figure 4) forms a dynamic link to the actin cytoskeleton [70,71]. Other molecules have also been found to become associated with the core complex. These include p120-catenin, which interacts directly with the membrane-proximal region of the cadherin cytoplasmic domain and may assemble non-receptor tyrosine kinases such as Fyn, Yes and Fer to the complex [72,73]. In addition, the tyrosine phosphatase PTP1B may be recruited to p120-catenin, at least in fibroblasts and neural cells which express N-cadherin instead of E-cadherin [74].




Figure 4
Regulation of adherens junction and β -catenin stability. **A**, Localization of β -catenin at the adherens junction occurs in a complex with E-cadherin and α -catenin. β -catenin is also present in the β -catenin-destruction complex where it is being degraded in the absence of Wnt ligand. **B**, Growth factor (GF) as well as oncogene mediated activation of kinases can phosphorylate two conserved tyrosine residues in the N- or C-terminus of β -catenin, leading to a disruption of the adherens complex and formation of a nuclear β -catenin complex. Once in the nucleus, β -catenin can replace co-repressors from TCF/LEF and thereby form activating transcriptional complexes. Activation of Wnt results in the stabilization of β -catenin and its nuclear accumulation where Wnt target genes are turned on (see text for details).

β -catenin has a second life in the canonical Wnt (wingless/int) cascade [75]. In the absence of a Wnt ligand, it is present in the " β -catenin-destruction complex", an assembly of proteins that includes the scaffolding protein Axin, adenomatous polyposis coli (APC) protein, casein kinase I α and glycogen synthase kinase-3 (GSK-3, [76]). GSK-3 phosphorylates β -catenin at serine/threonine residues N-terminal to the first armadillo repeat (Figure 4A, and see below). The phosphorylated motif allows the binding of a component of the E3 ubiquitin ligase, followed by ubiquitination and degradation by the proteasome. When Wnt signalling becomes activated, β -catenin escapes the degradation complex and migrates to the cell nucleus (Figure 4B). Since β -catenin does not bind to DNA itself, it has to form a complex with TCF/LEF (T-cell factor/lymphoid enhancer factor) transcription factors [77]. These complexes assemble components of the general transcription machinery and proteins involved in chromatin modification to induce the expression of a specific subset of gene targets which mainly determine cell proliferation and cell fate [78]. These include cyclin D1 and c-Myc which are up-regulated in colon cancers [78]. c-Myc is a key mediator of activated Wnt signalling in murine intestinal cancer [79]. GSK-3 family proteins (GSK-3 α and GSK-3 β) are constitutively active in resting cells. The transcription factor Snail has been identified as one target of GSK-3 leading to the nuclear export and destruction of Snail by the proteasome [80]. GSK-3 activity is suppressed in response to external signals and involves AKT-mediated phosphorylation at an N-terminal motif [81]. Inactivation of GSK-3 β by phosphorylation of the N-terminal serine might be involved in tumour progression because it leads to increased levels of c-Myc (cellular Myelocytomatosis, also called MYC, encoded by the MYC gene, [82]; see below). Knock-in mice where the N-terminally serines of GSK3 proteins were replaced by alanines had no defects in Wnt signalling indicating that GSK-3 activity in the Wnt pathway is regulated in a manner distinct from phosphorylation of the N-terminal serine that may involve disassembly of the β -catenin-destruction complex [83,84]. Another consequence of GSK-3 inactivation is that Snail will accumulate in the nucleus and repress E-cadherin expression (Figure 4B).

We addressed the functional consequences of weakening or destroying cell-to-cell adhesion in the adenomas of SP-C C-RAF BXB mice using two different genetic approaches, conditional ablation of the *Cdh1* gene in mice with a "floxed" *Cdh1* gene [85] or switchable expression of dominant negative E-cadherin. As expected, the ablation of functional E-cadherin caused deadhesion among tumour cells [54]. In addition, in a fraction of tumour cells, nuclear β -catenin was observed, indicating that upon removal of E-cadherin, β -catenin was not completely destroyed but transported to the nucleus. Thus, the release of β -catenin from the cadherin complex not only affected

the integrity and function of the adhesion complex, but may also have made it available for signalling in the nucleus. This observation is in line with a previous investigation in non-tumorous cells, where the formation of a transcriptional β -catenin complex has been observed upon loss of E-cadherin [86].

Increased tumour cell proliferation was observed in vivo, in line with the up-regulation of cyclin D1 and c-Myc in tumour cells 36 hours after induction of dominant negative E-cadherin [54]. After induction of dominant negative E-cadherin or inactivation of the *Cdh1* gene, massive formation of blood and lymph vessels, termed the "angiogenic switch" [87] was observed in the adenomas [54]. Vascular endothelial growth factors A and C were identified as β -catenin target genes in vivo and in NSCLC tumour cells [54]. The finding that vessel induction by dominant negative E-cadherin was reversible in the early phase of induction, but was no longer reversible after long-term ablation of E-cadherin may be explained by the eventual acquisition of a tumour vessel signature [88]. Vascularized tumours developed invasive fronts and gave rise to micrometastasis in thoracic lymph nodes and bone marrow. It is notable that the presence of micrometastases in lymph nodes in lung adenocarcinoma patients correlates with poorer outcomes as compared to those lacking detectable micrometastases [89]. Progression towards malignancy upon ablation of E-cadherin in epithelial tumour cells was not only observed in RAF-driven lung tumourigenesis [54] but also in a mouse breast cancer model with epithelium-specific inactivation of p53 [90]. Combined loss of E-cadherin and p53 led to accelerated development of invasive and metastatic mammary carcinomas [90].

Many roads to nuclear β -catenin signalling in cancer

Frequent mutational activation of Wnt/ β -catenin signalling has been observed in various types of human cancers [91]. With respect to genes specifying the adhesion complex, mutations in E-cadherin (*CDH1*) have been found in gastric and colon cancer but have not yet been reported in lung cancer. The most frequent colorectal cancer-associated genetic lesions are loss-of-function mutations in the *APC* gene and they result in sustained β -catenin signalling [91]. Activating mutations have also been identified in the *CTNNB1* gene, which encodes β -catenin, in colon cancer cells [92] as well as in melanoma cell lines [93]. In addition, deletions in exon 3 of *CTNNB1* have been detected in colorectal carcinomas and transcripts lacking exon 3 are translated into a stabilized β -catenin with dominant nuclear β -catenin signalling [94,95]. Colon-restricted conditional expression of stabilized β -catenin mutant in transgenic mice led to the formation of adenomatous intestinal polyps and colon microadenomas [96]. In human lung cancer, mutations have not been reported

for APC and are rare in *CTNNB1* (3%) [97]. Activation of Wnt signalling upstream of β -catenin has been observed in a low number of lung cancer samples [98]. Whether nuclear expression of β -catenin correlates with poor or better prognosis in NSCLC is unclear [98].

I will now discuss alternative mechanisms that may result in nuclear β -catenin signalling in cancer cells in the absence of overexpressed Wnt ligands or mutational activation in the canonical Wnt/ β -catenin signalling cascade. Repression of *CDH1* expression by epigenetic mechanisms might lead to a loss of E-cadherin function in the absence of *CDH1* loss-of-function mutations. Aberrant methylation of normally unmethylated CpG islands in the promoter regions of genes has been correlated with transcriptional inactivation of several genes in human cancer. Silencing of E-cadherin expression by promoter CpG methylation was found in a variety of human epithelial carcinoma cell lines [99]. In primary NSCLC cancers CpG island methylation was detected at a frequency of 18% with methylation-specific PCR [100]. Secondly, transcription factor-mediated suppression of E-cadherin expression might be at play. Indeed, Twist, a transcription factor that suppresses E-cadherin expression and cell-to-cell adhesion, has been found to be up-regulated in breast cancer [101]. The contribution of Twist towards malignancy may use as an additional mechanism the induction of miR-10b in breast cancer cells [102]. miR-10b belongs to the class of regulatory small cellular RNAs, termed microRNA (miRNA), that act as mediators of the RNA interference pathway. Twist-induced miR-10b, and miR-10b was found to inhibit the expression of the HOXD10 protein, permitting the expression of the pro-metastatic gene product, RHOC [102].

As a further possibility we have to consider that β -catenin may be released by phosphorylation from complexes at the membrane and subsequently enter the nuclear signalling pool. The three-dimensional structure of β -catenin and the structure of the cadherin/ β -catenin complex have been elucidated [103,104]. β -catenin has 12 armadillo repeats; each repeat is composed of three α -helices. The binding interface of β -catenin with E-cadherin involves armadillo repeats 5–12 whereas the interaction of β -catenin with the DNA binding factor TCF-4 uses armadillo repeats 3–8. Therefore, some flanking armadillo repeats of β -catenin would be suitable for posttranslational modifications that may disrupt specifically E-cadherin or α -catenin binding without ablating the interaction with TCF. As detailed below, phosphorylation of β -catenin at two critical tyrosine residues, tyrosine-142 and tyrosine-654, has been shown to disrupt the E-cadherin/ β -catenin adhesion complex with concomitant β -catenin nuclear activity (Figure 4). Since both modifications lie outside the interaction domain with LEF/TCFs, complex stability of β -cat-

enin with LEF/TCFs would not be affected by phosphorylation.

Cell surface transmembrane tyrosine kinase receptors modulate the adhesion complex by phosphorylation, as demonstrated for the EGFR [105]. This work showed that the EGFR is associated with the E-cadherin- β -catenin adhesion complex and that the receptor can phosphorylate β -catenin in vitro and in three epithelial cell lines. Furthermore, an association of β -catenin with receptor ERBB2 together with phosphorylation of β -catenin has been shown in gastric cancer cell lines [106-108]. Activated RAS has been shown to induce tyrosine phosphorylation of β -catenin leading to disruption of adherens junctions in an epithelial cell line [109]. In transgenic mice, intestinal expression of an oncogenic *K-RasG12V* allele in conjunction with a loss-of-function allele of APC was shown to increase nuclear β -catenin signalling [110]. This combination of genes led to increased intestinal tumour initiation and accelerated tumour progression [110]. Activation of the tyrosine kinase Src in epithelial MDCK (Madin-Darby canine kidney) cells impaired cell adherens junction function via phosphorylation of β -catenin [111]. Src has been shown to phosphorylate β -catenin on tyrosine-654 in vitro and evidence was provided that this phosphorylation is important for the disruption of the E-cadherin/ β -catenin complex in a colorectal cell line [112]. Furthermore, tyrosine-654 phosphorylation in vitro induced the formation of a β -catenin complex with the nuclear TATA binding protein [113]. Using a Src kinase inhibitor, tyrosine phosphorylation of β -catenin was blocked and expression of β -catenin target genes was reduced in a colorectal cancer cell line [114]. In addition, cell-to-cell adhesion was restored in the presence of the Src kinase inhibitor, whereas cell migration was strongly reduced [114]. In fibroblast cells, overexpression of another tyrosine kinase, Fer led to a disruption of adherens junction complexes [115].

Tyrosine-142 is present in the first armadillo repeat which overlaps with the α -catenin binding region of β -catenin. Phosphorylation of this residue induced the dissociation of α -catenin from the E-cadherin/ β -catenin complex with concomitant loss of cell aggregation [116]. Tyrosine-142 is phosphorylated by Fyn, Fer and Met, the tyrosine kinase cell surface receptor for hepatocyte growth factor (HGF). Stimulation of the Met receptor in conjunction with overexpression of Bcl 9-2, an adaptor protein that links β -catenin to transcriptional coactivators, in epithelial MDCK cells did not only disrupt cell-to-cell adhesion but pulled β -catenin from an adhesion complex into a nuclear complex with Bcl 9-2. Thus, phosphorylation of tyrosine-142 weakened α -catenin binding to β -catenin in favour of a nuclear β -catenin complex with Bcl 9-2 [117]. In primary hepatocytes, where a significant fraction of β -catenin is

bound to Met, HGF induced nuclear translocation of β -catenin [118]. We also have to consider that trimeric Met/E-cadherin/ β -catenin complexes may exist in cancer cells [119,120] and that Met activation may occur in a significant fraction of lung adenocarcinoma samples [121]. In NSCLC, intronic mutations occur in *MET* [122]. They lead to the expression of a receptor with a deleted juxtamembrane domain with sustained kinase activity after HGF stimulation [122]. Another possibility that might switch β -catenin from an adhesive into a signalling factor is a conformational change in the C-terminus of β -catenin [123]. In sum it is clear that there are additional routes to nuclear β -catenin signalling, parallel to the Wnt pathway. They operate by weakening the association of E-cadherin with β -catenin in the adhesion complex, using a variety of mechanisms and thus make β -catenin available as a nuclear signalling partner in cancer cells, including those present in lung adenocarcinoma. Further studies are required to define at what stage of tumourigenesis any of the proposed mechanisms are relevant.

β -catenin signalling and the induction of dysplasia

Why did the disseminated tumour cells forming a micrometastasis in compound mice with oncogenic RAF and disrupted adherens junctions fail to colonize and grow into a macrometastasis? One obvious explanation may be the failure of the micrometastasis to acquire a "metastasis virulence gene" that would allow for colonization in the new tissue [124]. A second possibility comes from observations in several human cancers showing that loss of E-cadherin function is accompanied by the expression of other cadherin family members, termed "cadherin switch" [125]. According to this model, tumour cells forming a micrometastasis have to re-establish adhesion at the new organ site in order to grow. The conditional transient re-expression of E-cadherin at the stage of micrometastasis should allow testing this hypothesis. A third scenario may be inappropriate β -catenin activity. When systemic, long-term activation of β -catenin signalling was induced in six week-old SP-C C-RAF BXB mice with lung adenomas via the expression of dominant negative E-cadherin, RT-PCR analysis of tumour cell mRNA revealed the expression of genes (*Cdx1*, *Atoh1*) that are normally expressed in the intestine indicating that an epigenetically-driven change in cell fate had occurred [54]. As it is not clear, whether the lung cells changed morphologically into intestine cells or acquired a broader range of pluripotency or self renewal activity, I shall call this form of epigenetic plasticity dysplasia [126]. During embryonic and postnatal organ development and cell differentiation, cell fate programmes are altered in response to extracellular cues. Under physiologic conditions, these cues (type and dose of signalling molecules) are provided by neighbouring cells or through the circulation. The cues manifest in the epigenetic regulation of gene expression by herita-

ble modification of the DNA (principally methylation of CpG dinucleotides) and through altering chromatin. Histone proteins function as building blocks that package the DNA into nucleosomes and distinct histone modifications form a "histone code" [127]. Modifications that condense chromatin, modify the access of transcription factors to DNA or recruit other complexes such as the Polycomb complex to chromatin, occur during development as well as in stem cells and cancer [128,129]. The modifications serve as cell fate-specific marks. They are generally passed on unchanged from one cell to its daughter cells and secure the faithful expression of differentiation-associated genes.

Therefore, it appeared that there may be no way back for a differentiated committed cell to an earlier fate after it has lost its pluripotent capacity. However, there are examples for transdifferentiation, the transformation of one differentiated cell into another [126]. Furthermore, epigenetic changes are reversible and have been experimentally induced by somatic cell nuclear transfer and cell fusion, and more recently via combined expression of four specific transcription factors, also termed "magic brew" [130]. The four factors (Oct3/4, Sox2, Klf4 and c-Myc, with c-Myc being an oncogene) reprogrammed mouse fibroblasts into induced pluripotent stem (iPS) cells that resemble embryonic stem cells in terms of morphology [131]. The achievement of bona fide reprogramming towards pluripotency was proven, since the iPS cells, after injection into early embryos, differentiated into all normal adult cell types [132-134]. While the first report [131] used drug selectable markers driven by promoters that are active in embryonic stem cells for the isolation of rare iPS cells, morphology alone can also be used to detect iPS clones [135]. It also appears that two of the factors, Myc and Klf-4 increase the frequency of reprogramming and are not strictly necessary [135,136].

The *MYC* proto-oncogenes are essential activators of cell proliferation and have emerged as some of the genes most commonly deregulated in cancer [137]. Activation of *MYC* genes in human cancer occurs by amplification or loss of transcriptional control, which results in *MYC* protein overexpression. In NSCLC, *MYC* gene copy number is found to be amplified in a fraction of specimen [8]. The up-regulation of c-Myc at the post-transcriptional level also appears to be of instrumental importance for c-Myc to promote tumour progression [138]. The half-life of c-Myc is controlled by a number of sequential, reversible phosphorylations on two conserved residues, serine-58 and serine-62. In response to MAPK signalling, c-Myc is phosphorylated on serine-62; parallel activation of PI3K/AKT leads to the inactivation of GSK3, with threonine-58 remaining unphosphorylated [82]. Active GSK-3 however can phosphorylate c-Myc on threonine-58 if serine-62 is

phosphorylated which subsequently may lead to its degradation through the activity and co-operation of other enzymes such as prolyl isomerase 1 and protein phosphatase 2A [138].

In transgenic mice expressing *Nmyc* from the SP-C promoter progenitor cells in the developing distal lung expanded in numbers and their differentiation was blocked leading to disturbed lung function and perinatal death [53]. SP-C promoter-directed overexpression of *c-Myc* in transgenic mice did not disturb lung development and induced tumour formation in the lung only after long latency [139], suggesting that a second hit, presumably the mutational activation of an oncogene, may be needed for tumour initiation. In contrast, conditional *Myc* overexpression in other tissues such as the haematopoietic system or the liver induced carcinomas with short latencies [140,141]. Importantly, abrogation of *Myc* expression caused tumour regression arguing against additional mutational events during carcinoma formation. When hepatocellular carcinoma cells or distant lung metastases derived from the carcinomas were transplanted under the skin of SCID mice, tumours engrafted in the recipient animals. The tumours regressed after abrogation of *Myc* expression and the residual scar tissue under the skin contained differentiated cells resembling hepatic lobules [141], indicating that the transplanted metastatic cells could regain their differentiated phenotype.

According to a classical model, *c-Myc* is a basic-helix-loop-helix zipper transcription factor that dimerizes with *Max* leading to the activation of genes that contain binding sites for *Myc-Max* complexes. The identification of thousands of putative *c-Myc* target genes [142], the finding that about half of all DNA sites binding *c-Myc* were intergenic (>10 kb away from transcriptional start sites [143], and the finding that *c-Myc* promotes DNA replication through a non-transcriptional mechanism with subsequent DNA damage [144] indicate that the classical model does not fully explain tumorigenic *c-Myc* function. Conditional disruption of *N-Myc* in distal lung epithelial cells inhibited distal lung proliferation and induced premature differentiation indicating that it is required for maintaining a distal population of undifferentiated, proliferating progenitor cells [53].

A form of epigenetic plasticity similar to that noted in adult mice with oncogenic *RAF*-driven lung tumours with disruption of adherens junctions and nuclear β -catenin signalling [54] had been observed before in embryonic lung epithelium in transgenic mice with SP-C promoter-directed expression of a constitutively active fusion protein of β -catenin and the transcription factor *Lef1* [145]. These lungs lacked differentiated lung cell types and showed a hyperproliferative epithelium expressing *Cdx1*,

Atoh1 and other genes normally expressed in intestinal epithelium. Another example of reprogramming has been observed upon introduction of activated β -catenin into either the common lymphoid or common myeloid progenitors [146]. Multipotential cells giving rise to both lymphoid and myeloid offspring were generated but apparently only single-step reversion in the developmental hierarchy had occurred, because upon grafting into irradiated mice, no full reconstitution was observed [146]. Therefore, the question arises whether step-wise reversion in epigenetically controlled developmental programmes of gene expression may contribute to malignancy. Indeed, it has been proposed, that tumour-restricted "recapitulation" of signatures that are normally restricted to embryonic development might contribute to neoplastic progression [147,148]. In line with this hypothesis, *Wnt* signalling has been proposed to increase the self-renewal capacity of haematopoietic stem cells [149]. However, two groups have recently reported [150,151] that inducible overexpression of a stabilized β -catenin increased the proliferation of haematopoietic cells as expected but led to an exhaustion of functional haematopoietic stem cell potency. Mechanistically, the loss of a haematopoietic stem cell signature (*HoxB4*, *Pu.1*, *Bmi-1* expression) was observed. Whether a similar stem cell-suppressive action is at play in lung tumours with oncogenic *C-RAF* and dominant-negative *E-cadherin* expression has to be determined.

Conclusion

Two recent studies have evaluated the consequences of the loss of *E-cadherin* in conjunction with either oncogenic *RAF* kinase expression or loss of *p53* for malignant progression of epithelial tumours. The investigation of the breast cancer model revealed that combined loss of *E-cadherin* and *p53* in mammary epithelial cells induced metastatic carcinoma that resembles invasive lobular carcinoma. In the lung NSCLC model, disruption of *E-cadherin* led to vascularized tumours that grew rapidly and gave rise to micrometastasis. Nuclear β -catenin signalling was instrumental for up-regulation of vascular endothelial growth factor expression and epigenetic plasticity. Published data are being reviewed on how receptor and non-receptor kinases impinge on the stability of the adherens junction complex. Evidence suggests that kinases may modulate nuclear β -catenin signalling. In a cooperative manner, kinases and nuclear β -catenin may be instrumental for the expression of gene targets in the lung which in turn is involved in malignant progression. I finally discuss what mechanisms may block the step from micrometastasis to macrometastasis and how *E-cadherin* function, together with oncogenic and nuclear β -catenin signalling might control this important step of malignancy.

List of abbreviations

APC: adenomatous polyposis coli; BADJ: bronchio-alveolar duct junction; BASC: bronchio-alveolar stem cell; CC: Clara cell; c-Myc: cellular Myelocytomatosis; EGFR: epidermal growth factor receptor; ERK: extracellular signal-regulated kinase; HGF: hepatocyte growth factor; LEF: lymphoid enhancer factor; MAPK: mitogen-activated protein kinase; MEK: MAP kinase extracellular signal-regulated kinase; NSCLC: non-small-cell lung cancer; PCR: polymerase chain reaction; PI3K: phosphoinositide-3-kinase; RT-PCR: reverse transcription- polymerase chain reaction; rTA: reverse transcriptional transactivator; SCID: severe combined immune deficiency; SP-C: surfactant protein-C; Sca1: stem cell antigen 1; TCF: T-cell factor; VEGF: vascular endothelial growth factor; Wnt: wingless/int.

Competing interests

The author declares that they have no competing interests.

Acknowledgements

I would like to thank my colleagues. Our research is supported by grants from Deutsche Krebshilfe e. V. – Dr. Mildred Scheel Stiftung für Krebsforschung (grant I07792) and by the DFG (grant TR17 B7). I apologize to those whose work was not cited due to space limitation.

References

- Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: **Cancer statistics, 2006.** *CA Cancer J Clin* 2006, **56**:106-130.
- Merrill RM, Weed DL: **Measuring the public health burden of cancer in the United States through lifetime and age-conditional risk estimates.** *Ann Epidemiol* 2001, **11**:547-553.
- Alberg AJ, Ford JG, Samet JM: **Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition).** *Chest* 2007, **132**:29S-55S.
- Sun S, Schiller JH, Gazdar AF: **Lung cancer in never smokers--a different disease.** *Nat Rev Cancer* 2007, **7**:778-790.
- Beckles MA, Spiro SG, Colice GL, Rudd RM: **Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes.** *Chest* 2003, **123**:97S-104S.
- Flieder DB, Vazquez M, Carter D, Brambilla E, Gazdar A, Noguchi M, Travis WD, Kramer A, Yankelevitz DF, Henschke Cl: **Pathologic findings of lung tumors diagnosed on baseline CT screening.** *Am J Surg Pathol* 2006, **30**:606-613.
- Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR: **A census of human cancer genes.** *Nat Rev Cancer* 2004, **4**:177-183.
- Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhi R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M: **Characterizing the cancer genome in lung adenocarcinoma.** *Nature* 2007, **450(7171)**:893-898.
- Meuwissen R, Linn SC, van V, Mooi WJ, Berns A: **Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene.** *Oncogene* 2001, **20**:6551-6558.
- Wang JC, Dick JE: **Cancer stem cells: lessons from leukemia.** *Trends Cell Biol* 2005, **15**:494-501.
- Clarke MF, Fuller M: **Stem cells and cancer: two faces of eve.** *Cell* 2006, **124**:1111-1115.
- Cardoso WV, Lu J: **Regulation of early lung morphogenesis: questions, facts and controversies.** *Development* 2006, **133**:1611-1624.
- Blenkinsopp WK: **Proliferation of respiratory tract epithelium in the rat.** *Exp Cell Res* 1967, **46**:144-154.
- Rawlins EL, Hogan BL: **Epithelial stem cells of the lung: privileged few or opportunities for many?** *Development* 2006, **133**:2455-2465.
- Liu X, Driskell RR, Engelhardt JF: **Stem cells in the lung.** *Methods Enzymol* 2006, **419**:285-321.
- Nogee LM: **Alterations in SP-B and SP-C expression in neonatal lung disease.** *Annu Rev Physiol* 2004, **66**:601-623.
- Giangreco A, Reynolds SD, Stripp BR: **Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction.** *Am J Pathol* 2002, **161**:173-182.
- Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S, Crowley D, Bronson RT, Jacks T: **Identification of bronchioalveolar stem cells in normal lung and lung cancer.** *Cell* 2005, **121**:823-835.
- Theise ND, Henegariu O, Grove J, Jagirdar J, Kao PN, Crawford JM, Badve S, Saxena R, Krause DS: **Radiation pneumonitis in mice: a severe injury model for pneumocyte engraftment from bone marrow.** *Exp Hematol* 2002, **30**:1333-1338.
- Hay J, Shahzeidi S, Laurent G: **Mechanisms of bleomycin-induced lung damage.** *Arch Toxicol* 1991, **65**:81-94.
- Kasper M, Haroske G: **Alterations in the alveolar epithelium after injury leading to pulmonary fibrosis.** *Histol Histopathol* 1996, **11**:463-483.
- Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhi R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Janne PA, Girard L, Minna J, Christiani D, Li C, Sellers WR, Meyerson M: **Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.** *Cancer Res* 2005, **65**:5561-5570.
- Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M: **EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.** *Science* 2004, **304**:1497-1500.
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA: **Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.** *N Engl J Med* 2004, **350**:2129-2139.
- Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R: **The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.** *Br J Cancer* 2004, **91**:355-358.
- Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M: **Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.** *PLoS Med* 2005, **2**:e313.
- Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt KA, Liniker E, Borgman CL, Haringsma HJ, Feng W, Weir BA, Lowell AM, Lee JC, Wolf J, Shapiro GI, Wong KK, Meyerson M, Thomas RK: **The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.** *Oncogene* 2007, **26**:5023-5027.
- Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, Brackenbury L, Butler A, Clarke O, Cole J, Dicks E, Dike A, Drozdz A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K, Kosmidou V, Lugg R, Menzies A, Perry J, Petty R, Raine K, Ratford L, Shepherd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widada S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Knowles M, Leung SY, Louis DN, Looijenga LH, Malkowicz B, Pierotti MA, Teh B, Chenevix-Trench G, Weber BL, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futreal PA, Wooster R, Stratton MR: **Lung cancer: intragenic ERBB2 kinase mutations in tumours.** *Nature* 2004, **431(7008)**:525-526.

29. Tichelaar JW, Lu W, Whitsett JA: **Conditional expression of fibroblast growth factor-7 in the developing and mature lung.** *J Biol Chem* 2000, **275**:11858-11864.
30. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Janne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK: **The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.** *Cancer Cell* 2006, **9**:485-495.
31. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE: **Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.** *Genes Dev* 2006, **20**:1496-1510.
32. Repasky GA, Chenette EJ, Der CJ: **Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?** *Trends Cell Biol* 2004, **14**:639-647.
33. Malumbres M, Barbacid M: **RAS oncogenes: the first 30 years.** *Nat Rev Cancer* 2003, **3**:459-465.
34. Downward J: **Targeting RAS signalling pathways in cancer therapy.** *Nat Rev Cancer* 2003, **3**:11-22.
35. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, Campuzano V, Barbacid M: **Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context.** *Cancer Cell* 2003, **4**:111-120.
36. Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M, Benguria A, Zaballos A, Flores JM, Barbacid M, Beach D, Serrano M: **Tumour biology: senescence in premalignant tumours.** *Nature (London)* 2005, **436**:642.
37. Sakamoto H, Shimizu J, Horio Y, Ueda R, Takahashi T, Mitsudomi T, Yatabe Y: **Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.** *J Pathol* 2007, **212**:287-294.
38. Schreck R, Rapp UR: **Raf kinases: oncogenesis and drug discovery.** *Int J Cancer* 2006, **119**:2261-2271.
39. McKay MM, Morrison DK: **Integrating signals from RTKs to ERK/MAPK.** *Oncogene* 2007, **26**:3113-3121.
40. Wellbrock C, Karasirides M, Marais R: **The RAF proteins take centre stage.** *Nat Rev Mol Cell Biol* 2004, **5**:875-885.
41. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: **Mutations of the BRAF gene in human cancer.** *Nature (London)* 2002, **417**:949-954.
42. Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Min WS, Kim SH, Lee JY, Yoo NJ, Lee SH: **Mutational analysis of the ARAF gene in human cancers.** *APMIS* 2005, **113**:54-57.
43. Emuss V, Garnett M, Mason C, Marais R: **Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.** *Cancer Res* 2005, **65**:9719-9726.
44. Rapp UR, Huleihel M, Pawson A, Minna JD, Fanning-Heidecker G, Cleveland JL, Beck T, Forchhammer J, Storm SM: **Role of raf oncogenes in lung carcinogenesis.** *J Int Assoc for the Study of Lung Cancer* 1988, **4**:162-167.
45. McPhillips F, Mullen P, MacLeod KG, Sewell JM, Monia BP, Cameron DA, Smyth JF, Langdon SP: **Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells.** *Carcinogenesis* 2006, **27**:729-739.
46. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M: **A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors.** *Genes Dev* 2007, **21**:379-384.
47. Ji H, Wang Z, Perera SA, Li D, Liang MC, Zaghul S, McNamara K, Chen L, Albert M, Sun Y, Al Hashem R, Chirieac LR, Padera R, Bronson RT, Thomas RK, Garraway LA, Janne PA, Johnson BE, Chin L, Wong KK: **Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.** *Cancer Res* 2007, **67**:4933-4939.
48. Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, Rapp UR: **Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein.** *Cell Growth Diff* 2000, **11**:185-190.
49. Bohinski RJ, Di Lauro R, Whitsett JA: **The lung-specific surfactant protein B gene promoter is a target for thyroid transcription factor 1 and hepatocyte nuclear factor 3, indicating common factors for organ-specific gene expression along the foregut axis.** *Mol Cell Biol* 1994, **14**:5671-5681.
50. Kwei KA, Kim YH, Girard L, Kao J, Pacyna-Gengelbach M, Salari K, Lee J, Choi YL, Sato M, Wang P, Hernandez-Boussard T, Gazdar AF, Petersen I, Minna JD, Pollack JR: **Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer.** *Oncogene* 2008.
51. Minoo P, Su G, Drum H, Bringas P, Kimura S: **Defects in tracheoesophageal and lung morphogenesis in Nkx2.1(-/-) mouse embryos.** *Dev Biol* 1999, **209**:60-71.
52. Wert SE, Glasser SW, Korfhagen TR, Whitsett JA: **Transcriptional elements from the human SP-C gene direct expression in the primordial respiratory epithelium of transgenic mice.** *Dev Biol* 1993, **156**:426-443.
53. Okubo T, Knoepfler PS, Eisenman RN, Hogan BL: **Nmyc plays an essential role during lung development as a dosage-sensitive regulator of progenitor cell proliferation and differentiation.** *Development* 2005, **132**:1363-1374.
54. Ceteci F, Ceteci S, Karremann C, Kramer BW, Asan E, Götz R, Rapp UR: **Disruption of Tumor Cell Adhesion Promotes Angiogenic Switch and Progression to Micrometastasis in RAF-driven Murine Lung Cancer.** *Cancer Cell* 2007, **12**(2):145-159.
55. Fedorov LM, Papadopoulos T, Tyrsin OY, Twardzik T, Götz R, Rapp UR: **Bcl-2 determines susceptibility to induction of lung cancer by oncogenic CRaf.** *Cancer Res* 2002, **62**:6297-6303.
56. Götz R, Kramer BW, Camarero G, Rapp UR: **BAG-1 haplo-insufficiency impairs lung tumorigenesis.** *BMC Cancer* 2004, **24**:85.
57. Fedorov LM, Papadopoulos T, Tyrsin OY, Twardzik T, Götz R, Rapp UR: **Loss of p53 in craf induced transgenic lung adenoma leads to tumor acceleration and phenotypic switch.** *Cancer Res* 2003, **63**:2268-2277.
58. Suzuki K, Nagai K, Yoshida J, Yokose T, Kodama T, Takahashi K, Nishimura M, Kawasaki H, Yokozaki M, Nishiwaki Y: **The prognosis of resected lung carcinoma associated with atypical adenomatous hyperplasia: a comparison of the prognosis of well-differentiated adenocarcinoma associated with atypical adenomatous hyperplasia and intrapulmonary metastasis.** *Cancer* 1997, **79**:1521-1526.
59. Hawkins PT, Anderson KE, Davidson K, Stephens LR: **Signaling through Class I PI3Ks in mammalian cells.** *Biochem Soc Trans* 2006, **34**:647-662.
60. Manning BD, Cantley LC: **AKT/PKB signaling: navigating downstream.** *Cell* 2007, **129**:1261-1274.
61. Lin X, Bohle AS, Dohrmann P, Leuschner I, Schulz A, Kremer B, Fandrich F: **Overexpression of phosphatidylinositol 3-kinase in human lung cancer.** *Langenbecks Arch Surg* 2001, **386**:293-301.
62. Brognard J, Clark AS, Ni Y, Dennis PA: **Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.** *Cancer Res* 2001, **61**:3986-3997.
63. Tang JM, He QY, Guo RX, Chang XJ: **Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.** *Lung Cancer* 2006, **51**:181-191.
64. Cully M, You H, Levine AJ, Mak TW: **Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis.** *Nat Rev Cancer* 2006, **6**:184-192.
65. Marsit CJ, Zheng S, Aldape K, Hinds PW, Nelson HH, Wiencke JK, Kelsey KT: **PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration.** *Hum Pathol* 2005, **36**:768-776.
66. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J: **Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.** *Cell* 2007, **129**:957-968.
67. Takeichi M: **Morphogenetic roles of classic cadherins.** *Curr Opin Cell Biol* 1995, **7**:619-627.

68. Stappert J, Kemler R: **A short core region of E-cadherin is essential for catenin binding and is highly phosphorylated.** *Cell Adhes Commun* 1994, **2**:319-327.
69. Chen YT, Stewart DB, Nelson WJ: **Coupling assembly of the E-cadherin/beta-catenin complex to efficient endoplasmic reticulum exit and basal-lateral membrane targeting of E-cadherin in polarized MDCK cells.** *J Cell Biol* 1999, **144**:687-699.
70. Drees F, Pokutta S, Yamada S, Nelson WJ, Weis WI: **Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly.** *Cell* 2005, **123**:903-915.
71. Yamada S, Pokutta S, Drees F, Weis WI, Nelson WJ: **Deconstructing the cadherin-catenin-actin complex.** *Cell* 2005, **123**:889-901.
72. Kim L, Wong TW: **The cytoplasmic tyrosine kinase FER is associated with the catenin-like substrate pp120 and is activated by growth factors.** *Mol Cell Biol* 1995, **15**:4553-4561.
73. Piedra J, Miravet S, Castano J, Palmer HG, Heisterkamp N, Garcia H, Dunach M: **p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin interaction.** *Mol Cell Biol* 2003, **23**:2287-2297.
74. Xu G, Craig AW, Greer P, Miller M, Anastasiadis PZ, Lilien J, Balsamo J: **Continuous association of cadherin with beta-catenin requires the non-receptor tyrosine-kinase Fer.** *J Cell Sci* 2004, **117**:3207-3219.
75. Nelson WJ, Nusse R: **Convergence of Wnt, beta-catenin, and cadherin pathways.** *Science* 2004, **303**:1483-1487.
76. Price MA: **CKI, there's more than one: casein kinase I family members in Wnt and Hedgehog signaling.** *Genes Dev* 2006, **20**:399-410.
77. Nusse R: **Wnt signaling in disease and in development.** *Cell Res* 2005, **15**:28-32.
78. Willert K, Jones KA: **Wnt signaling: is the party in the nucleus?** *Genes Dev* 2006, **20**:1394-1404.
79. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, Reed KR, Vass JK, Athineos D, Clevers H, Clarke AR: **Myc deletion rescues Apc deficiency in the small intestine.** *Nature* 2007, **446**(7136):676-679.
80. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC: **Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition.** *Nat Cell Biol* 2004, **6**:931-940.
81. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: **Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.** *Nature* 1995, **378**(6559):785-789.
82. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR: **Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.** *Genes Dev* 2000, **14**:2501-2514.
83. McManus EJ, Sakamoto K, Armit LJ, Ronaldson L, Shpiro N, Marquez R, Alessi DR: **Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis.** *EMBO J* 2005, **24**:1571-1583.
84. Liu X, Rubin JS, Kimmel AR: **Rapid, Wnt-induced changes in GSK3beta associations that regulate beta-catenin stabilization are mediated by Galpha proteins.** *Curr Biol* 2005, **15**:1989-1997.
85. Boussadia O, Kutsch S, Hierholzer A, Delmas V, Kemler R: **E-cadherin is a survival factor for the lactating mouse mammary gland.** *Mech Dev* 2002, **115**:53-62.
86. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R: **E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation.** *J Cell Sci* 1999, **112** (Pt 8):1237-1245.
87. Bergers G, Benjamin LE: **Tumorigenesis and the angiogenic switch.** *Nat Rev Cancer* 2003, **3**:401-410.
88. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW: **Genes expressed in human tumor endothelium.** *Science* 2000, **289**:1197-1202.
89. Osaki T, Oyama T, Gu CD, Yamashita T, So T, Takenoyama M, Sugio K, Yasumoto K: **Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer.** *J Clin Oncol* 2002, **20**:2930-2936.
90. Derksen PW, Liu X, Saridin F, van der GH, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AV, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J: **Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.** *Cancer Cell* 2006, **10**:437-449.
91. Giles RH, van Es JH, Clevers H: **Caught up in a Wnt storm: Wnt signaling in cancer.** *Biochim Biophys Acta* 2003, **1653**:1-24.
92. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW: **Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.** *Science* 1997, **275**:1787-1790.
93. Rubinfeld B, Robbins P, El Gamil M, Albert I, Porfiri E, Polakis P: **Stabilization of beta-catenin by genetic defects in melanoma cell lines.** *Science* 1997, **275**:1790-1792.
94. Iwao K, Nakamori S, Kameyama M, Imaoka S, Kinoshita M, Fukui T, Ishiguro S, Nakamura Y, Miyoshi Y: **Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations.** *Cancer Res* 1998, **58**:1021-1026.
95. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW: **Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.** *Cancer Res* 1998, **58**:1130-1134.
96. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, Taketo MM: **Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene.** *EMBO J* 1999, **18**:5931-5942.
97. Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R, Yokota J: **Constitutive activation of the Wnt signaling pathway by CTNGB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma.** *Genes Chromosomes Cancer* 2001, **30**:316-321.
98. Mazieres J, He B, You L, Xu Z, Jablons DM: **Wnt signaling in lung cancer.** *Cancer Lett* 2005, **222**:1-10.
99. Oda T, Kanai Y, Oyama T, Yoshiura K, Shimoyama Y, Birchmeier W, Sugimura T, Hirohashi S: **E-cadherin gene mutations in human gastric carcinoma cell lines.** *Proc Natl Acad Sci U S A* 1994, **91**:1858-1862.
100. Zochbauer-Muller S, Fong KM, Virmani AK, Gerads J, Gazdar AF, Minna JD: **Aberrant promoter methylation of multiple genes in non-small cell lung cancers.** *Cancer Res* 2001, **61**:249-255.
101. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: **Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.** *Cell* 2004, **117**:927-939.
102. Ma L, Teruya-Feldstein J, Weinberg RA: **Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.** *Nature* 2007, **449**(7163):682-688.
103. Huber AH, Nelson WJ, Weis WI: **Three-dimensional structure of the armadillo repeat region of beta-catenin.** *Cell* 1997, **90**:871-882.
104. Huber AH, Weis WI: **The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin.** *Cell* 2001, **105**:391-402.
105. Hoschuetzky H, Aberle H, Kemler R: **Beta-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor.** *J Cell Biol* 1994, **127**:1375-1380.
106. Shibata T, Ochiai A, Kanai Y, Akimoto S, Gotoh M, Yasui N, Machinami R, Hirohashi S: **Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells.** *Oncogene* 1996, **13**:883-889.
107. Ochiai A, Akimoto S, Kanai Y, Shibata T, Oyama T, Hirohashi S: **c-erbB-2 gene product associates with catenins in human cancer cells.** *Biochem Biophys Res Commun* 1994, **205**:73-78.
108. Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, Hirohashi S: **c-erbB-2 gene product directly associates with beta-catenin and plakoglobin.** *Biochem Biophys Res Commun* 1995, **208**:1067-1072.
109. Kinch MS, Clark GJ, Der CJ, Burrridge K: **Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia.** *J Cell Biol* 1995, **130**:461-471.
110. Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, Smits R, Louvard D, Fodde R, Robine S: **APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression.** *Gastroenterology* 2006, **131**:1096-1109.
111. Behrens J, Vakaet L, Friis R, Winterhager E, Van Roy F, Mareel MM, Birchmeier W: **Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine phosphorylation of the**

- E-cadherin/beta-catenin complex in cells transformed with a temperature-sensitive v-SRC gene.** *J Cell Biol* 1993, **120**:757-766.
112. Roura S, Miravet S, Piedra J, Garcia H, Dunach M: **Regulation of E-cadherin/Catenin association by tyrosine phosphorylation.** *J Biol Chem* 1999, **274**:36734-36740.
 113. Piedra J, Martinez D, Castano J, Miravet S, Dunach M, de Herreros AG: **Regulation of beta-catenin structure and activity by tyrosine phosphorylation.** *J Biol Chem* 2001, **276**:20436-20443.
 114. Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C, Gambacorti-Passerini C: **SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling.** *Cancer Res* 2006, **66**:2279-2286.
 115. Rosato R, Veltmaat JM, Groffen J, Heisterkamp N: **Involvement of the tyrosine kinase fer in cell adhesion.** *Mol Cell Biol* 1998, **18**:5762-5770.
 116. Ozawa M, Kemler R: **Altered cell adhesion activity by pervanadate due to the dissociation of alpha-catenin from the E-cadherin.catenin complex.** *J Biol Chem* 1998, **273**:6166-6170.
 117. Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hamerschmidt M, Birchmeier W: **Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions.** *Genes Dev* 2004, **18**:2225-2230.
 118. Monga SP, Mars WM, Padiaditakis P, Bell A, Mule K, Bowen WC, Wang X, Zarnegar R, Michalopoulos GK: **Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes.** *Cancer Res* 2002, **62**:2064-2071.
 119. Hiscox S, Jiang WG: **Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells.** *Biochem Biophys Res Commun* 1999, **261**:406-411.
 120. Reshetnikova G, Troyanovsky S, Rimm DL: **Definition of a direct extracellular interaction between Met and E-cadherin.** *Cell Biol Int* 2007, **31**:366-373.
 121. Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J, Fukayama M: **c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis.** *Cancer Sci* 2007, **98**:1006-1013.
 122. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, Holcomb T, Pujara K, Stinson J, Fu L, Severin C, Rangell L, Schwall R, Amler L, Wickramasinghe D, Yauch R: **Somatic mutations lead to an oncogenic deletion of met in lung cancer.** *Cancer Res* 2006, **66**:283-289.
 123. Gottardi CJ, Gumbiner BM: **Distinct molecular forms of beta-catenin are targeted to adhesive or transcriptional complexes.** *J Cell Biol* 2004, **167**:339-349.
 124. Nguyen DX, Massague J: **Genetic determinants of cancer metastasis.** *Nat Rev Genet* 2007, **8**:341-352.
 125. Cavallaro U, Christofori G: **Cell adhesion and signalling by cadherins and Ig-CAMs in cancer.** *Nat Rev Cancer* 2004, **4**:118-132.
 126. Slack JM: **Metaplasia and transdifferentiation: from pure biology to the clinic.** *Nat Rev Mol Cell Biol* 2007, **8**:369-378.
 127. Strahl BD, Allis CD: **The language of covalent histone modifications.** *Nature*. 2000, **403(6765)**:41-45.
 128. Sparmann A, van Lohuizen M: **Polycomb silencers control cell fate, development and cancer.** *Nat Rev Cancer* 2006, **6**:846-856.
 129. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G: **Genome regulation by polycomb and trithorax proteins.** *Cell* 2007, **128**:735-745.
 130. Rossant J: **Stem cells: the magic brew.** *Nature* 2007, **448(7151)**:260-262.
 131. Takahashi K, Yamanaka S: **Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.** *Cell* 2006, **126**:663-676.
 132. Okita K, Ichisaka T, Yamanaka S: **Generation of germline-competent induced pluripotent stem cells.** *Nature* 2007, **448(7151)**:313-317.
 133. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R: **In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state.** *Nature* 2007, **448(7151)**:318-324.
 134. Maherali N, Sridharan R, Xie W, Utikal J, Eminli S, Arnold K, Stadtfeld M, Yachechko R, Tchiew J, Jaenisch R, Plath K, Hochedlinger K: **Directly Reprogrammed Fibroblasts Show Global Epigenetic Remodeling and Widespread Tissue Contribution.** *Cell Stem Cell* 2007, **1**:55-70.
 135. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ: **Reprogramming of human somatic cells to pluripotency with defined factors.** *Nature (London)* 2007.
 136. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochizuki Y, Takizawa N, Yamanaka S: **Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts.** *Nat Biotechnol* 2008, **26**:101-106.
 137. Adhikary S, Eilers M: **Transcriptional regulation and transformation by Myc proteins.** *Nat Rev Mol Cell Biol* 2005, **6**:635-645.
 138. Arnold HK, Sears RC: **A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins.** *Cancer Metastasis Rev* 2008.
 139. Ehrhardt A, Bartels T, Geick A, Klocke R, Paul D, Halter R: **Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c-myc and epidermal growth factor in alveolar type II pneumocytes.** *Br J Cancer* 2001, **84**:813-818.
 140. Felsher DW, Bishop JM: **Reversible tumorigenesis by MYC in hematopoietic lineages.** *Molecular Cell* 1999, **4**:199-207.
 141. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, Yang Q, Bishop JM, Contag CH, Felsher DW: **MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.** *Nature* 2004, **431(7012)**:1112-1117.
 142. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F: **The c-Myc target gene network.** *Semin Cancer Biol* 2006, **16**:253-264.
 143. Bieda M, Xu X, Singer MA, Green R, Farnham PJ: **Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genome.** *Genome Res* 2006, **16**:595-605.
 144. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R: **Non-transcriptional control of DNA replication by c-Myc.** *Nature* 2007, **448(7152)**:445-451.
 145. Okubo T, Hogan BL: **Hyperactive Wnt signaling changes the developmental potential of embryonic lung endoderm.** *J Biol* 2004, **3**:11.
 146. Baba Y, Garrett KP, Kincade PW: **Constitutively active beta-catenin confers multilineage differentiation potential on lymphoid and myeloid progenitors.** *Immunity* 2005, **23**:599-609.
 147. Prehn RT: **The role of mutation in the new cancer paradigm.** *Cancer Cell Int* 2005, **5**:9.
 148. Rapp UR, Ceteci F, Schreck R: **Oncogene-induced plasticity and cancer stem cells.** *Cell Cycle* 2007, **7**:45-51.
 149. Reya T, Duncan AW, Ailles L, Domen J, Scherer DC, Willert K, Hintz L, Nusse R, Weissman IL: **A role for Wnt signalling in self-renewal of haematopoietic stem cells.** *Nature (London)* 2003, **423**:409-414.
 150. Kirstetter P, Anderson K, Porse BT, Jacobsen SE, Nerlov C: **Activation of the canonical Wnt pathway leads to loss of hematopoietic stem cell repopulation and multilineage differentiation block.** *Nat Immunol* 2006, **7**:1048-1056.
 151. Scheller M, Huelsken J, Rosenbauer F, Taketo MM, Birchmeier W, Tenen DG, Leutz A: **Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation.** *Nat Immunol* 2006, **7**:1037-1047.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

